الكاتب: Multiple References

Moxifloxacin is a new 8-methoxy-quinolone with a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, anaerobes and atypical organisms such as Mycoplasma and Chlamydia spp. Fluorquinolones are considered to have a concentrationdependent effect, although a time-dependent bactericidal effect against some Gram-positive bacteria has also been described (Spreng et al., 1995; Cester et al., 1996). They also have some characteristics such as a wide spectrum of bactericidal activity, a large volume of distribution, low plasma protein binding and relatively low MICs against susceptible target microorganisms (Spreng et al., 1995; Brown, 1996). In recent years many pharmacokinetic studies of fluorquinolones have been carried out in several species (Marangos et al., 1997; Aliabadi & Lees, 2001; Abd El-Aty et al., 2005; Gaur et al., 2004; Seguin et al., 2004). Recent studies in humans demonstrate excellent clinical efficacy of moxifloxacin, showing high systemic bioavailability, extensive distribution to pulmonary tissues and fluids, and a low incidence of gastrointestinal side effects (Stass & Kubitza, 1999; Stass, 1999; Ball, 2000; Blondeau & Hansen, 2001).